Cleveland Biolabs to report on current work at BIO conference

Cleveland Biolabs said on Thursday that it will present data on its oncology and bio-defense programs next week at the 2015 BIO CEO & Investor Conference in New York.

The company's presentation is scheduled to take place on Tuesday at 2 p.m. EST. Its CEO, Yakov Kogan, will lead the presentation, which will be available on the company's website,, in the investors section.

Cleveland Biolabs focuses on the development of pharmaceuticals for diseases that pose a significant threat to health and conditions with limited or no treatment options. The company's flagship products in development are entolimod and Curaxin CBL0137. The first is a countermeasure against radiation that the company said may have the potential as a treatment for cancer. The latter is the primary treatment candidate produced by the company in its oncology division. It utilizes suppression methods in major cellular pathways that can suppress malignant cell growth. It has been shown to be beneficial in animal testing and is currently in the first phase of its clinical trials.

The company maintains partnerships with the Roswell Park Cancer Institute, the Cleveland Clinic and the Children's Cancer Institute in Australia. The company also has business ties to both the U.S. and the Russian Federation through its three subsidiaries: Incuron, LLC; BioLabs 612, LLC; and Panacela Labs, Inc.

Organizations in this Story

Cleveland Biolabs

Want to get notified whenever we write about Cleveland Biolabs ?
Next time we write about Cleveland Biolabs, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.